drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-edited autologous T cells)
drug_description
Gene-edited autologous T-cell therapy in which CRISPR/Cas9 inserts a CD19-specific STAR receptor at the TRAC locus and ablates the endogenous TCR; the receptor signals via the native TCR–CD3 complex with OX40 costimulation to target CD19+ malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are CRISPR/Cas9-edited to disrupt the endogenous TRAC and knock in a CD19-specific STAR receptor that grafts an anti-CD19 scFv onto TCR constant regions. This enables HLA-independent recognition of CD19 while signaling through the native TCR–CD3 complex with OX40 costimulation, driving activation, proliferation, and cytotoxic killing of CD19+ malignant B cells; TCR ablation reduces alloreactivity and GVHD risk.
drug_name
Autologous CD19-STAR-T cells
nct_id_drug_ref
NCT05631912